PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage. PCSK9 adheres to the epidermal growth factor-like repeat A...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Pharm Bull
Autors principals: Sobati, Saeideh, Shakouri, Amir, Edalati, Mahdi, Mohammadnejad, Daryoush, Parvan, Reza, Masoumi, Javad, Abdolalizadeh, Jalal
Format: Artigo
Idioma:Inglês
Publicat: Tabriz University of Medical Sciences 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539318/
https://ncbi.nlm.nih.gov/pubmed/33062601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.34172/apb.2020.062
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars